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A matrix system was developed that releases ibuprofen (IB) over a 12-hour period and the influence of 
the polymer type and concentration on the release rate of the drug was evaluated. Tablets containing 
different concentrations of Carbopol (CP), hydroxypropyl methylcellulose (HPMC), or ethyl cellulose 
(EC) were prepared using direct compression and the drug content, content uniformity, hardness, 
friability, dissolution performance, and in vitro release kinetics were examined. Formulated tablets 
were found to be within acceptable limits for physical and chemical parameters. The release kinetics of 
the Carbopol®971P 8% formulation showed the best linearity (r2 =0.977) in fitting zero-order kinetics, 
suggesting the release rate was time independent. The drug release from tablets containing 8% CP was 
extended over approximately 18 hours and the release kinetics were nearly linear, suggesting that this 
system has the potential to maintain constant plasma drug concentrations over 12 hours, which could 
reduce the frequency of administration and the occurrence of adverse effects associated with repeated 
administration of conventional IB tablets.
Uniterms: Ibuprofen/study. Ibuprofen/sustained release tablets. Ibuprofen/formulation/carbopol. 
Ibuprofen/formulation/hydroxypropyl methylcellulose. Ibuprofen/formulations/ethyl cellulose. Ibuprofen/
formulations/release kinetics.
INTRODUCTION
Oral administration of drugs is generally preferred, 
especially over parenteral administration. Oral products are 
produced in a more cost-effective manner in comparison 
with parenteral products, and account for approximately 
60% of all prescription products worldwide (Advanced 
oral, 2011).
Sustained-release oral drug products are designed to 
slowly release the active ingredient over an extended time 
following administration, and offer significant advantages 
over conventional orally administered products, including 
reduced dosing frequency and decreased drug plasma-
concentration fluctuations (Charman et al., 2002; 
Moodley et al., 2012). Matrix formulations of hydrophilic 
and/or hydrophobic polymers have been used to control 
the release of drugs (Malmsten, 2002; Qiu, Bae, 2006) 
and can be produced using conventional processing 
equipment.
Hydrophilic matrices hydrate following oral 
administration and form a gelatinous layer that acts as 
a barrier to control the rate of drug release (Rabasco, 
1999; Bernard et al., 2004; Rajabi, Rane, Felton, 2013). 
Hydroxypropyl methylcellulose (HPMC) is one of the most 
common hydrophilic polymers used in matrix systems 
(Tiwari, Rajabi-Siahboomi, 2008). High molecular weight 
Carbopol (CP) polymers at relatively low levels (3–30%) 
have also been employed (Lubrizol Advanced Materials, 
2008). Ethyl cellulose (EC) hydrophobic polymer control 
drug release predominately through the formation of a 
network of capillaries or channels.
The objective of this study was to investigate the 
influence of the polymer type and concentration on the 
release rate of ibuprofen (IB), a first-line nonsteroidal anti-
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inflammatory drug (NSAID) that is used in the treatment 
of rheumatic diseases to reduce the symptoms of chronic 
inflammation and pain. IB has poor water solubility and is 
a good candidate for formulation into a modified release 
system because of its short half-life (approximately2 
hours) (Burke, Smyth, Fitzgerald, 2007; Furst, Ulrich, 
Varkey, 2009; Raffa, 2005; Sweetman, 2007). The overall 
goal was to develop a matrix system that will release the 
drug over a 12-hour period. The release kinetics were 
also studied to better understand the influence of polymer 
composition on the mechanism of drug release from the 
matrices.
MATERIAL AND METHODS
IB was obtained from Astroquim, S.A. de C.V. 
(Ecatepec, México) and IB standard from Sigma-
Aldrich. Carbopol® 971P was a gift from Lubrizol 
Advanced Materials (Cleveland OH, USA). ETHOCEL 
N-50 and METHOCEL E4M were gifts from Gylsa and 
manufactured by Dow Chemical Company (Midland MI, 
USA). Microcrystalline cellulose (MCC), magnesium 
stearate, talc, colloidal silicon dioxide, and sodium lauryl 
sulfate were from Desarrollo de Especialidades Químicas, 
S.A. de C.V. (Monterrey, México).
 The compositions of the formulations are shown in 
Table I. Experimental batches of 0.5 kg of each formulation 
were prepared. The amounts of the excipients in the 
formulations were determined from preliminary studies 
based on the powder mixtures during the manufacturing 
process and the percentage of each polymer that gave the 
best flow characteristics and non-stick properties was 
selected. The type and amount of formulation components 
in the mixture were selected to allow for manufacturing 
by direct compression. For comparison, commercially 
available immediate-release IB tablets (Productos 
Farmacéuticos Collins, S.A. de C.V., Jalisco, México) 
were obtained from a local pharmacy.
IB, polymers, MCC, and sodium lauryl sulfate 
were sieved through a #25 sieve and blended for 15 min 
in a polyethylene bag. Talc and magnesium stearate were 
sieved, added to the drug/polymer blend, and mixed for 
three minutes. Final powder blends were compressed using 
16 mm punches on a 10-station rotary tablet press (ADEPT 
10D mini-press, Mumbai, India).
Physical properties of the tablets
Ten tablets were taken at random from each batch 
and subjected to tablet hardness testing using a Vankel 200 
hardness tester (Cary N.C., USA). Standard deviations (SD) 
and relative standard deviations (RSD) were calculated from 
the data. An additional ten tablets were randomly selected 
from each batch for friability testing. Tablets were weighed, 
placed in the friabilator (Vankel 41-1200), and subjected 
to 25 rotations per minute for 4 minutes. Loose powder 
was removed and the remaining tablets were reweighed 
to determine a weight loss percentage, following the U.S. 
Pharmacopeia method (USP, 2015).
Content and content uniformity
Ten tablets from each batch were randomly selected 
for drug content analysis. Tablets were weighed then 
ground to a fine powder. An amount equivalent to 100 mg 
of IB powder based on theoretical loading was weighed 
and transferred to a 100 mL volumetric flask, 50 mL 
of phosphate buffer pH 7.2 was added. The flask was 
subjected to ultrasonication for 60 min and the volume 
was completed with the same buffer solution. The resulting 
TABLE I - Composition of matrix tablets of IB used in this study
C1 C2 C3 H1 H2 H3 E1 E2
IB 60.50 59.00 57.50 44.50 49.50 54.50 44.50 44.50
Carbopol®971P 5 6.50 8 1 1 1 1 1
Hydroxypropylmethylcellulose - - - 30 15 10 - -
Ethylcellulose - - - - - - 30 20
Microcrystaline cellulose 30 30 30 20 30 30 20 30
Colloidal silicon dioxide 1 1 1 1 1 1 1 1
Talc 2.50 2.50 2.50 2.50 2.50 2.50 2.50 2.50
Sodium lauryl sulfate 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50
Magnesium stearate 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50
Percentage 100 100 100 100 100 100 100 100
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solution was filtered and the first few milliliters of the 
filtrate were discarded. The filtered solution was analyzed 
using a UV Spectrophotometer at 265 nm (Varian Inc. 
Cary 50; California, USA). The absorbance obtained 
was then converted to the amount of IB using a standard 
calibration curve prepared with an IB standard of 1 mg 
mL-1 in the same medium. 
In vitro dissolution
In vitro dissolution studies were carried out 
according to the USP paddle method. The dissolution 
medium was 900 mL of phosphate buffer (pH 7.2) 
previously degassed, at 37.0 + 0.5 °C, and a stirring speed 
of 50 rpm was used. A six-vessel dissolution apparatus 
(Vankel VK 7000, Cary, N.C., USA) was used and six 
randomly selected tablets from each batch were tested. 
Drug release was monitored at intervals of 2 hours; 
samples were filtered with hydrophilic polyvinylidene 
fluoride (PVDF) acrodiscs of 0.45 μm prior to UV-VIS 
spectrophotometric analysis at 265 nm (spectrophotometer 
Varian Inc. Cary 50) using a previously validated method 
of quantification (linearity, precision, and accuracy were 
assessed). Data were graphed as cumulative percentage 
drug release (calculated from the total amount of IB in 
each formulation) versus time. The f2 similarity factor, 
calculated from Eq. 1, was then used to compare the 
dissolution data (Shah et al., 1998).
 
Analysis of the in vitro release kinetics
The following kinetic models were used to evaluate 
the in vitro drug release: zero order (Eq. 2), first order (Eq. 
3), Higuchi (Eq. 4), and Korsmeyer-Peppas (Eq. 5).
 Qt = Q0 + k0t (2)
 logQt = logQ0 – k1t / 2.303 (3)
 Qt = kHt1/2 (4)
 Mt / M∞ = ktn (5)
where: Qt is the amount of drug dissolved over time 
t, Q0 is the initial amount of drug in solution (equal to 
zero), k0 is the zero order release constant (expressed as 
concentration/time), the constant k1 is first order (expressed 
in time units, h-1), kHt1/2 is the dissolution constant of the 
Higuchi equation (expressed in time units, h1/2), Mt is the 
amount of drug released at time t, M∞ is the total amount of 
drug released at infinite time, k is the release rate constant 
(expressed as h-n) and n is the release exponent which 
indicates the type of release mechanism.
Validation of the analytical method
NORMA Oficial Mexicana NOM-177-SSA1-2013, 
(NOM 177, 2013) was used to demonstrate whether 
the dissolution test method was adequate. The test was 
validated following assessment of linearity, precision 
(repeatability and intermediate precision), and accuracy. 
Linearity was obtained from the correlation 
coefficient of three standard curves using five different 
buffered solutions with concentrations of 0.06-0.6 mg mL-1 
of IB. A stock solution of IB (1 mg mL-1) was prepared 
by dissolution in pH 7.2 buffer solution. Solutions with 
concentrations of 0.06, 0.1, 0.2, 0.4, and 0.6 mg mL-1 were 
prepared for triplicate studies of precision and accuracy; 
absorbance was determined at 265 nm. Linearity was 
evaluated by linear regression analysis using the least 
squares regression method (a regression coefficient > 0.99 
is required). 
The repeatability (intra-assay precision) and 
intermediate precision (interday precision) were calculated 
by analysis of two known standard solutions of IB on 
different days. Each solution was prepared and analyzed 
in triplicate in a UV-VIS spectrophotometer on two 
consecutive days, in the same spectrophotometer, by the 
same operator. Relative standard deviation (RSD) was 
used to calculate the precision of the method (<3% RSD 
is required). 
The accuracy was expressed as the agreement 
between the set reference value and the measured value of 
each concentration. IB concentrations of 0.6, 0.1, 0.2, 0.4, 
and 0.6 mg mL-1 were analyzed in triplicate in a UV-VIS 
spectrophotometer (<3% RSD on each point is required).
RESULTS AND DISCUSSION
To assess the linearity of the method, calibration 
curves of IB concentration versus absorbance were 
plotted, giving a correlation coefficient of approximately 
0.9997 over the concentration range studied (0.06–0.6 
mg mL-1). The representative linear equation was y = 
1.786x + 0.012. IB concentration measurement accuracy 
was determined by same- (intraday) and alternate-
day (interday) spectrophotometry in dissolution test 
standardized conditions. The average recovery was 98.60–
101.79%. The RSD values were less than 3%, indicating 
that the precision of the dissolution procedure and analysis 
method was acceptable (México, 2013).
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Direct compression tableting is a very cost-effective 
method to produce tablets. Benefits include reduced 
processing times, fewer manufacturing steps, decreased 
labor costs, and less power consumption. In contrast, 
wet granulation is considered to be a relatively laborious 
process, despite its other advantages, and involves 
considerable material handling, additional processing 
steps, and energy costs (Niazi, 2009; Summers, Aulton, 
2007). The current study uses a direct compression 
technique to produce matrix tablets to investigate the 
influence of polymer type and concentration on the release 
rate of a model poorly water-soluble drug. The model drug, 
IB, also has poor powder flow properties (Costa, Sousa, 
2001). The addition of excipients, such as talc and colloidal 
silicon dioxide, also called “flow promoters”, helps to 
improve the flowability of powder blends, reducing the 
phenomena of adhesion and cohesion between particles. 
The sliding effect of colloidal silicon dioxide is because of 
its very small particle size, which allows attachment to the 
surface of other ingredients to reduce interparticle friction; 
however, talc exerts its sliding effect by reducing adhesive 
force between the surface-IB particles (Liu et al., 2008; 
Staniforth, Aulton, 2007). In the current study, both of 
these excipients were employed to improve the flowability 
of the powder blend. The percentage of colloidal silicon 
dioxide used (1%)was within the recommended limits 
specified in the Handbook of Excipients (Rowe, Sheskey, 
Quinn, 2009) for use as a glidant. The amount of talc in the 
formulations was maintained at 2.5%, a concentration high 
enough to show the desired effect on powder adhesion, 
but low enough not to cause segregation from the powder 
mixture. Microcrystalline cellulose, at concentrations of 
20% and 30%, was used to improve the compressibility 
of the powder blends. Note that although the total tablet 
weight varied, the target of 400 mg of drug per tablet was 
held constant.
Table II shows the results of the physical evaluation 
of the tablets from the different formulation batches. All 
tablets investigated in the study exhibited a hardness of 
>15 kp. Although there is not a USP specification for 
hardness, a minimum hardness of 4 kp is considered 
sufficient to obtain physically stable tablets that are not 
likely to break during routine handling. The friability of 
all tablets was less than 1%, indicating that the tablets 
would have sufficient physical stability during packing, 
transportation, and handling (USP, 2015). IB is known to 
exhibit poor tableting behavior because of its hydrophobic 
structure, low flowability, and tendency to stick to the 
tablet punches, all of which have been shown to lead to 
variations in tablet weight (Bushra et al., 2008). In the 
current study, the drug content ranged from approximately 
99% to 104% of theoretical. In addition, the RSD ranged 
from 0.48 to 1.33 and were well within the USP acceptance 
criteria (<6% RSD) for content uniformity for all tablet 
formulations.
Figure 1 shows the release profi les of the 
formulations containing HPMC as the primary rate-
controlling polymer in comparison with an immediate-
release formulation IR. The tablets containing up to 30% 
HPMC showed very slow and incomplete drug release 
from the matrix over the time of the study. An f2 similarity 
evaluation confirmed that these formulations did not have 
similar release profiles, with values of less than 50.The H3 
formulation (10% HPMC) released the largest amount of 
drug, but the percentage of drug dissolved was less than 
60%, meaning that at the end of the release profile study 
(12 hours) 40% of the drug remained in the tablet. In 
contrast, drug release was rapid and complete from the 
immediate-release formulation. 
Drug release from hydrophilic matrices generally 
occurs by diffusion through the gelatinous layer, erosion 
of the matrix (i.e. dissolution of the polymer), or a 
TABLE II - Physical evaluation of tablets from the different formulations
Formulation
Weight (mg) 
Mean±S.D. 
n=10
Hardness (kp) 
Mean±S.D. 
n=10
Friability 
(%) weigth loss 
n=10
Drug content 
(%) IB±S.D. 
n=10
RSD 
Content uniformity
C1 644.57±6.54 17.68±0.55 0.24 102.56±1.36 1.33
C2 671.97±6.37 19.06±0.55 0.15 98.90±0.81 0.83
C3 693.97±8.36 21.66±1.08 0.17 104.71±1.10 1.06
H1 885.92±5.58 16.22±0.45 0.48 101.62±0.68 0.68
H2 806.81±6.80 18.95±0.57 0.26 101.23±0.55 0.55
H3 730.56±3.17 16.58±0.47 0.24 101.48±0.51 0.48
E1 889.20±9.40 23.17±0.79 0.35 101.07±0.79 0.79
E2 892.44±6.64 26.77±1.23 0.23 101.45±0.61 0.60
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combination of the two, depending on the solubility of 
the drug (Harris et al., 2006). Because IB is poorly water 
soluble, drug release from the HPMC matrix system is 
likely to be predominately controlled by the dissolution 
rate of the polymer. Note that the grade of HPMC used 
in the developed formulations was METHOCELE 4M, 
a relatively high molecular weight polymer with a high 
viscosity (about 4000 cps for a 2% solution) (Rowe, 
Sheskey, Quinn, 2009). A lower molecular weight grade 
of the same polymer (e.g. K100LVCR or METHOCELE 
50LV, with viscosities of approximately 100 and 50 cP, 
respectively) may be used to achieve a faster erosion 
(dissolution of the polymer matrix) rate and thus a faster 
drug release rate (Rowe, Sheskey, Quinn, 2009; Tiwari, 
Dinunzio, Rajabi, 2011). 
The dissolution results of the matrix formulations 
containing CP as the primary rate-controlling polymer are 
shown in Figure 2. 
CP is a cross-linked acrylic acid polymer that 
differs structurally from linear polymers such as HPMC, 
and is capable of forming gels at lower concentrations 
(Lubrizol Advanced Materials, 2008). The formulations 
with CP showed rapid gel formation in the dissolution 
media due to ionization of the carboxylic acid functional 
groups (Nizar, Hatim, Wasfy, 2011). This rapid gelation, 
as evidenced by less than 6% of drug being released within 
the first hour of the dissolution test, minimizes the burst 
effect common with HPMC matrices. When 5% CP was 
used, approximately 90% of the IB was released over a 
6-hour period. However, when the polymer concentration 
was increased to 6.5% and 8% (C2 and C3, respectively), 
the release of IB was much slower and extended for over 
12 hours. An f2 similarity evaluation confirmed that these 
formulations did not have similar profiles (f2< 50).
It should be noted that CP used in low concentrations 
(<3%) also improved the physical characteristics of the 
tablets, giving increases in tablet hardness and lower 
friability at lower compression forces. A minor tendency 
to stick on the punch faces was observed when this 
polymer was included in the EC and HPMC formulations. 
The CP levels in all tablet formulations were kept low 
to avoid effects on the dissolution; thus, the release of 
IB was predominantly dependent on the main (highest 
concentration) polymers used (Lubrizol Advanced 
Materials, 2011).
Figure 3 shows the dissolution profiles of matrix 
formulations containing 20% and 30% EC as the primary 
rate-controlling polymer. 
The EC matrix tablets showed similar dissolution 
profiles (f2= 89), irrespective of the concentration of the 
FIGURE 1 – In vitro release of tablets containing IB IR and 
HPMC as the main rate-controlling polymer. (X) IB IR; (∆) 
10% HPMC; (×) 15% HPMC; (♦) 30% HPMC.
FIGURE 2 – In vitro release of tablets containing IB IR and 
Carbopol®971P as the rate-controlling polymer. (X) IB IR; (♦) 
5% CP; (×) 6.5% CP; (∆) 8% CP.
FIGURE 3 - In vitro release of tablets containing IB IR and EC 
as the main rate-controlling polymer. (X) IB IR; (∆) 20% EC; 
(♦) 30% EC.
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polymer, with approximately 90% of the drug released 
after 8 hours. It should be noted that the dissolution 
profiles of the EC-based formulations were different to the 
profiles of the matrices containing either HPMC or CP, as 
evidenced by f2 values of less than 50. Interestingly, drug 
release from the EC matrix exhibited bimodal behavior: 
the first 4 hours showed a relatively fast release of IB 
(75% of the drug released at hour four), then a slow release 
phase. However, the E1 formulation contained a higher 
amount of MCC (30%), which when tableted produced 
slightly harder tablets (23.17 kp) compared with the 
E2 formulation (average hardness of 26.77 kp). Tablet 
hardness can influence the rate at which water permeates 
into the tablet and thus how quickly the drug releases 
from the system. The amount of MCC incorporated in the 
matrix tablets may have an effect on the deformation of 
the polymer particles (average particle size of 305 µm) 
during compression and therefore affect the porosity of 
the tablet, with higher MCC concentrations creating a 
less porous matrix (Tiwari, Dinunzio, Rajabi, 2011). The 
type of the polymers and the nature of excipients, such as 
MCC; as well as the physical properties of the granules, 
such as the specific surface area, shape, and hardness, 
can significantly affect the rate of dissolution of drugs 
contained in a formulation (Reddy, Mutalik, Reddy, 2003).
In this study, the hardness of all the tablets investigated 
had no direct effect on drug release. Although the EC 
tablets had the highest hardness values they showed faster 
IB release than the other formulations. Table III shows 
the dissolution similarity factor values for the different 
formulations; in all cases, there was no similarity to the 
reference formulation. 
In modified-release systems, understanding the 
drug-release mechanisms of different dosage forms is 
necessary to optimize the tablet design (Bernard et al., 
2004; Dash et al., 2010). Table IV shows the values of r2 
and the rate constants obtained for the different kinetic 
models of all of the formulations investigated in this 
study. Figures 4-7 show analysis of the linear regression 
graphs corresponding to different kinetic models from 
the dissolution profile of C3, the formulation containing 
the highest level of Carbopol. The slopes of the lines 
correspond to the release rate constants (k) in the zero-
order and Higuchi models, while the value for k in 
the first-order model was obtained from the equation: 
slope = –k/2.303.The value of the release exponent (n) is 
related to the slope of the line in the Korsmeyer-Peppas 
model.
The release kinetics of the C3 formulation showed 
the best linearity (r2 =0.977) in fitting zero-order kinetics, 
suggesting the release rate was time independent. As 
TABLE III - f2 Values from the different formulations
Formulation F2 value
C1 25.5
C2 48.4
C3 44.8
H1 24.7
H2 31.8
H3 37.3
E1 25.5
E2 25.5
FIGURE 4 - First-order release model of C3.
FIGURE 5 - Zero-order release model of C3.
FIGURE 6 - Higuchi release model of C3.
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reported (Varelas, Dicon, Stediner, 1995), these models 
fit hydrophilic matrix systems containing poorly water-
soluble drugs. In addition, the value of the release exponent 
n in the Korsmeyer-Peppas model approached a value of 
one, which corresponds to a case II transport mechanism, 
where drug release is predominately controlled by polymer 
relaxation and erosion. It is interesting to note that the 
formulations containing less CP (C1 and C2) had lower 
r2 values in the zero-order release model, suggesting that 
higher levels of this polymer are necessary to achieve time-
independent drug release. These results are in agreement 
with previously published data (Lubrizol Advanced 
Materials, 2011).
In contrast to the CP formulations, the formulations 
containing the hydrophobic EC (E1 and E2) showed a best 
fit to first-order kinetics (r2 =0.961 and 0.973, respectively) 
and the exponent value n from the Korsmeyer-Peppas 
model ranged between 0.5 and 1, indicating a combination 
of diffusion and erosion mechanisms. This so-called 
anomalous diffusion (non Fickian) was likely due to 
swelling and relaxation of the EC in the dissolution 
media. A study using matrix tablets of IB and EC found 
that diffusion was the predominant mechanism of drug 
release (Chandran, Asghar, Mantha, 2008; Lopes, Sousa, 
Costa, 2006).
The value of the diffusional exponent n for the 
H3formulation indicates a Fickian diffusion–type release 
mechanism for the IB. Fickian diffusional release shows 
a rapid initial release, followed by a decrease in release 
owing to a chemical potential gradient (Bernard et al., 
2004; Harris et al., 2006; Singh et al., 2012). These 
findings are in agreement with previous reports that have 
shown that poorly soluble drugs are released mainly by 
attrition mechanisms from hydrophilic and swellable 
polymeric matrices (Vueba et al., 2005).Table IV shows 
the values of r2 and the rate constants obtained from the 
different kinetic models for the formulations investigated 
in this study. 
CONCLUSIONS
Matrix tablets containing a model poorly water-
soluble compound IB formulated with a hydrophilic, 
rate-controlling polymer (CP®971P) at concentrations 
above 6.5% could be prepared by direct compression. 
These tablets showed drug release over a 12-hour time 
period. The rapid gelation of the CP polymer prevented 
the initial burst effect commonly observed with HPMC 
and EC matrices. Moreover, at the highest Carbopol 
concentration (8%), drug release generally followed 
zero-order kinetics, suggesting that this system has the 
potential to maintain a constant plasma concentration 
of IB over 12hours, which could reduce the frequency 
of administration and the occurrence of adverse effects 
associated with repeated administration of conventional 
IB tablets. Further research, however, is needed to 
investigate whether such a system will follow zero-order 
kinetics in vivo.
FIGURE 7 -Korsmeyer-Peppas model for the mechanism of 
drug release.
TABLE IV - Kinetics parameters calculated
Formulation
Zero Order First Order Higuchi Korsmeyer-Peppas 
r2 k0 (h-1) r2 k1 (h-1) r2 kH (h-1/2) r2N kKP (h- n)
C1 0.769 7.88 0.973 0.5803 0.880 38.07 0.908 1.031 0.0773
C2 0.956 8.02 0.89 0.2210 0.901 37.49 0.966 1.437 0.0211
C3 0.977 6.48 0.828 0.2072 0.926 33.81 0.957 1.101 0.0433
H1 0.983 1.26 0.979 0.0138 0.945 5.19 0.970 0.569 0.0434
H2 0.940 1.87 0.951 0.0230 0.988 8.07 0.994 0.466 0.0895
H3 0.867 2.82 0.909 0.0552 0.946 12.37 0.976 0.259 0.3332
E1 0.784 5.78 0.973 0.2395 0.893 27.83 0.918 0.583 0.2224
E2 0.789 5.87 0.961 0.2256 0.898 28.26 0.922 0.612 0.2036
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